Neoplasms, Second Primary

"Neoplasms, Second Primary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.

Descriptor ID	D016609
MeSH Number(s)	C04.692
Concept/Terms	Neoplasms, Second Primary Neoplasms, Second Primary Neoplasm, Second Primary Second Primary Neoplasm Metachronous Second Primary Neoplasms Neoplasms, Metachronous Second Primary Neoplasms, Metachronous Second Malignancy Malignancies, Second Malignancy, Second Second Malignancies Second Neoplasm Neoplasm, Second Neoplasms, Second Second Neoplasms Second Primary Neoplasms Metachronous Neoplasms Metachronous Neoplasm Neoplasm, Metachronous Neoplasms, Metachronous Second Primary Neoplasms, Therapy-Associated Neoplasms, Therapy-Associated Neoplasm, Therapy-Associated Neoplasms, Therapy Associated Therapy-Associated Neoplasm Neoplasms, Treatment-Associated Neoplasm, Treatment-Associated Neoplasms, Treatment Associated Treatment-Associated Neoplasm Neoplasms, Treatment-Related Neoplasm, Treatment-Related Neoplasms, Treatment Related Treatment-Related Neoplasm Therapy-Related Neoplasms Therapy Related Neoplasms Treatment-Associated Neoplasms Treatment Associated Neoplasms Treatment-Related Neoplasms Treatment Related Neoplasms Neoplasms, Therapy-Related Neoplasm, Therapy-Related Neoplasms, Therapy Related Therapy-Related Neoplasm Therapy-Associated Neoplasms Therapy Associated Neoplasms Therapy-Associated Cancer Therapy-Associated Cancer Cancer, Therapy-Associated Cancers, Therapy-Associated Therapy Associated Cancer Therapy-Associated Cancers Therapy-Related Cancer Cancer, Therapy-Related Cancers, Therapy-Related Therapy Related Cancer Therapy-Related Cancers Treatment-Related Cancer Cancer, Treatment-Related Cancers, Treatment-Related Treatment Related Cancer Treatment-Related Cancers Treatment-Associated Cancer Cancer, Treatment-Associated Cancers, Treatment-Associated Treatment Associated Cancer Treatment-Associated Cancers Cancer, Second Primary Cancer, Second Primary Cancers, Second Primary Second Primary Cancer Second Primary Cancers Second Cancer Cancer, Second Cancers, Second Second Cancers

Below are MeSH descriptors whose meaning is more general than "Neoplasms, Second Primary".

Diseases [C]
Neoplasms [C04]
Neoplasms, Second Primary [C04.692]

Below are MeSH descriptors whose meaning is related to "Neoplasms, Second Primary".

Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Second Primary".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasms, Second Primary" by people in this website by year, and whether "Neoplasms, Second Primary" was a major or minor topic of these publications.

Bar chart showing 95 publications over 28 distinct years, with a maximum of 7 publications in 2001 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	2	1	3
1996	2	2	4
1998	2	0	2
1999	3	0	3
2000	1	1	2
2001	5	2	7
2002	2	1	3
2004	3	1	4
2005	2	0	2
2006	4	1	5
2007	3	2	5
2008	4	1	5
2009	4	1	5
2010	2	1	3
2011	2	0	2
2012	1	1	2
2013	2	1	3
2014	2	0	2
2015	0	3	3
2016	2	0	2
2017	1	1	2
2018	3	1	4
2019	5	1	6
2020	1	0	1
2021	2	0	2
2022	7	0	7
2023	5	0	5
2024	0	1	1

Below are the most recent publications written about "Neoplasms, Second Primary" by people in Profiles.

Banner L, Rohan TZ, Zachian R, Gross T, Yang HY, Joffe D, Porcu P, Nikbakht N. Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate cancers after diagnosis of primary cutaneous B-cell lymphoma: A Surveillance, Epidemiology, and End Results database analysis. J Am Acad Dermatol. 2024 Jul; 91(1):151-153.

View in: PubMed
Mancarella C, Morrione A, Scotlandi K. PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas. Int J Mol Sci. 2023 Nov 15; 24(22).

View in: PubMed
Monda S, Pratsinis M, Lui H, Noel O, Chandrasekar T, Evans CP, Dall'Era MA. Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery. Eur Urol Focus. 2024 May; 10(3):448-453.

View in: PubMed
Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer. 2023 08; 11(8).

View in: PubMed
Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757.

View in: PubMed
Reyngold M, Karam SD, Hajj C, Wu AJ, Cuaron J, Lobaugh S, Yorke ED, Dickinson S, Jones B, Vinogradskiy Y, Shukla-Dave A, Do RKG, Sigel C, Zhang Z, Crane CH, Goodman KA. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2023 09 01; 117(1):53-63.

View in: PubMed
Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2?and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163.

View in: PubMed
Ripa V, Smith F, Goodman JW. Case of metastatic epithelioid haemangioendothelioma from an unknown primary site associated with membranous nephropathy and hypercoagulable state. BMJ Case Rep. 2022 Aug 22; 15(8).

View in: PubMed
Goldberg RM, Adams R, Buyse M, Eng C, Grothey A, Andr? T, Sobrero AF, Lichtman SM, Benson AB, Punt CJA, Maughan T, Burzykowski T, Sommeijer D, Saad ED, Shi Q, Coart E, Chibaudel B, Koopman M, Schmoll HJ, Yoshino T, Taieb J, Tebbutt NC, Zalcberg J, Tabernero J, Van Cutsem E, Matheson A, de Gramont A. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. J Natl Cancer Inst. 2022 06 13; 114(6):819-828.

View in: PubMed
Yang JCH, Brose MS, Castro G, Kim ES, Lassen UN, Leyvraz S, Pappo A, L?pez-R?os F, Reeves JA, Fellous M, Penault-Llorca F, Rudzinski ER, Tabatabai G, Vassal G, Drilon A, Trent J. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. BMC Cancer. 2022 Jun 07; 22(1):625.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement